Higher Serum THC Did Not Mean Stronger Pain-Related Effects After Repeated CBD in Rats

Repeated CBD–THC treatment reduced later sensitivity to THC’s pain-related effects in a rat experiment, despite altered serum cannabinoid concentrations. A higher parent-drug level cannot automatically be translated into a stronger response.

Behavior and chemistry were assessed separately

Male and female rats received THC alone or with CBD during a short repeated-treatment regimen. THC dose-response testing used thermal tail withdrawal and paw pressure. Serum measurements assessed parent THC and metabolites, including in a separate group not given the final test-day THC challenge.

The combination did not prevent the loss of effect

Compared with THC alone, repeated CBD plus THC produced greater shifts in selected THC dose-response curves. CBD also increased serum THC in relevant comparisons while reducing 11-hydroxy-THC and THC-COOH. These compounds have different pharmacological meanings and should not be collapsed into a total THC number.

More than one explanation remained possible

The authors discussed altered THC metabolism, enhanced tolerance and an antagonistic effect emerging with repeated CBD. The design did not definitively separate those mechanisms. A concentration difference therefore could not by itself explain the behavioral result.

Clinical transfer needs caution

The regimen lasted only four days of repeated treatment, doses differed by sex and administration did not reproduce every human product. Serum is not whole blood, and rodent pain responses are not driving or a patient-reported clinical outcome. The study argues against assuming that CBD necessarily preserves THC analgesia, while leaving the effects of other formulations, schedules and populations open.

Related analysis: evaluating cannabis tolerance claims.

Primary research

Greene NZ; Wiley JL; Yu Z; Clowers BH; Craft RM. Cannabidiol modulation of antinociceptive tolerance to Δ9-tetrahydrocannabinol. Psychopharmacology (2018). DOI: 10.1007/s00213-018-5036-z.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A CB1 Mutation Changed Cannabinoid Tolerance Differently Across Testing Methods

A receptor mutation delayed tolerance to WIN55,212-2 more consistently than to CP55,940, and the result also depended on how tolerance was measured. Fixed-dose behavior and dose-response shifts were different tests. Two agonists and several endpoints Investigators compared desensitization-resistant S426A/S430A mice with controls in thermal, formalin and chemotherapy-neuropathy experiments. Both challenge…

Spread the love

Read Article: A CB1 Mutation Changed Cannabinoid Tolerance Differently Across Testing Methods

Endocannabinoid Enzyme Inhibition Delayed Neuropathy Without Permanently Preventing It

Two FAAH inhibitors suppressed pain-related behavior during treatment, but neuropathy emerged after restricted preventive dosing stopped. Delaying an endpoint was not the same as permanently preventing the condition. Indirect cannabinoid-system modulation Researchers compared brain-permeant URB597, peripherally restricted URB937 and a direct synthetic agonist in paclitaxel-treated mice. FAAH inhibition alters endogenous…

Spread the love

Read Article: Endocannabinoid Enzyme Inhibition Delayed Neuropathy Without Permanently Preventing It

A GPR55 Barrier Study Did Not Demonstrate THC-Induced Blood–Brain Barrier Injury

A study of GPR55 activation changed experimental barrier measurements, but its test substance was lysophosphatidylinositol, not THC. A cannabinoid-related receptor label cannot substitute for the actual exposure. Cells and animals answered different questions Researchers examined rat brain microvascular endothelial cells using calcium, electrical-resistance and junction-related measurements. Animal experiments also assessed…

Spread the love

Read Article: A GPR55 Barrier Study Did Not Demonstrate THC-Induced Blood–Brain Barrier Injury

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us